Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat ...

Carlsmed, a spine surgery solution company, announced today that it launched its initial public offering with the start of an ...

McGraw Hill aims for a $4.2 billion valuation in its IPO, planning to raise $537 million to repay debt and expand its ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $26.5, a high estimate of $36.00, and a low estimate of $20.00. This current average represents a 31.17% ...